Search

Your search keyword '"Brandt, Alexander"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Brandt, Alexander" Remove constraint Author: "Brandt, Alexander" Topic fos: clinical medicine Remove constraint Topic: fos: clinical medicine
47 results on '"Brandt, Alexander"'

Search Results

1. sj-docx-11-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

2. sj-pdf-2-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

3. sj-docx-13-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

4. sj-docx-12-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

5. sj-docx-17-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

6. sj-docx-18-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

7. sj-docx-19-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

8. sj-docx-16-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

9. sj-docx-9-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

10. sj-docx-12-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

11. sj-docx-17-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

12. sj-pdf-3-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

13. sj-docx-8-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

14. sj-docx-14-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

15. sj-docx-8-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

16. sj-docx-15-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

17. sj-docx-18-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

18. sj-docx-19-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

19. sj-docx-11-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

20. sj-pdf-1-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

21. sj-docx-9-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

22. sj-pdf-2-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

23. sj-pdf-1-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

24. sj-docx-15-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

25. sj-pdf-4-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

26. sj-docx-16-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

27. sj-docx-10-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

28. sj-pdf-3-msj-10.1177_13524585221097296 – Supplemental material for Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

29. sj-pdf-2-msj-10.1177_13524585211032801 – Supplemental material for Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders

30. sj-pdf-1-msj-10.1177_13524585211032801 – Supplemental material for Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders

31. sj-pdf-2-msj-10.1177_13524585211032801 – Supplemental material for Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders

32. sj-pdf-4-msj-10.1177_13524585211032801 – Supplemental material for Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders

33. sj-pdf-3-msj-10.1177_13524585211003479 – Supplemental material for Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation

34. sj-pdf-1-msj-10.1177_13524585211003479 – Supplemental material for Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation

35. sj-pdf-4-msj-10.1177_13524585211032801 – Supplemental material for Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders

36. sj-pdf-2-msj-10.1177_13524585211003479 – Supplemental material for Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation

37. sj-pdf-1-mso-10.1177_2055217321998060 - Supplemental material for A novel investigation method for axonal damage in neuromyelitis optica spectrum disorder: In vivo corneal confocal microscopy

38. sj-pdf-1-msj-10.1177_13524585211003479 – Supplemental material for Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation

39. sj-pdf-1-msj-10.1177_13524585211032801 – Supplemental material for Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders

40. sj-pdf-3-msj-10.1177_13524585211032801 – Supplemental material for Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders

41. sj-pdf-1-mso-10.1177_2055217321998060 - Supplemental material for A novel investigation method for axonal damage in neuromyelitis optica spectrum disorder: In vivo corneal confocal microscopy

42. sj-pdf-3-msj-10.1177_13524585211032801 – Supplemental material for Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders

43. sj-pdf-3-msj-10.1177_13524585211003479 – Supplemental material for Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation

44. MSO915480 Supplemental Material - Supplemental material for Evaluation of the ‘ring sign’ and the ‘core sign’ as a magnetic resonance imaging marker of disease activity and progression in clinically isolated syndrome and early multiple sclerosis

45. MSO903474 Supplemental material - Supplemental material for High-dose vitamin D supplementation in multiple sclerosis – results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial

46. Supplemental material for Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study

47. Supplemental Table2 - Supplemental material for Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders

Catalog

Books, media, physical & digital resources